Filtered By:
Condition: Atrial Fibrillation
Drug: Pradaxa
Countries: New Zealand Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 6 results found since Jan 2013.
The changing use of anticoagulants in New Zealand
CONCLUSIONS: The introduction of the DOACs was expected to reduce the use of warfarin. However, the rapid rise in DOAC use was not predicted. The increase is most likely in patients with atrial fibrillation with the positive benefit of reducing the incidence of embolic stroke. However, having a high proportion of the elderly population (15% of people over 75-years) on anticoagulants has implications for the health sector, making hospital admissions and surgery more complex.PMID:35728215
Source: New Zealand Medical Journal - June 21, 2022 Category: General Medicine Authors: Paul Harper Alison Chang Matt Stephens Source Type: research
